PSS3 Baseline Characteristics and Vitreoretinal Interface Features in Patients with Vitreomacular Traction and Macular Hole from the MIVI-TRUST Clinical Program  by Lescrauwaet, B. et al.
A502  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
versus those with associated MH. This analysis establishes the representativeness 
of the MIVI-TRUST patient population in the context of clinical practice.
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Objectives: Atopic Dermatitis (AD) is a chronic relapsing skin condition and one 
of the most common skin diseases worldwide. Nowadays, the prevalence of AD is 
estimated to be between 5%-and-30% in children. AD onset is commonly before 
5years old in children. Therapeutic treatments include topical corticosteroids (CS) 
and long-term emollients as first-line therapy, followed by topical calcineurin inhibi-
tors. Emollients represent one of the cornerstones of treatments for patients with 
AD. The aims of this study were to compare the drug related management and 
the drug related costs between children with AD treated by at least an emollient 
(composed-of-Glycerol [15 gr], Vaseline [8 gr] and liquid-paraffin [2gr] per 100 gr) 
and children not treated by emollient. MethOds: This was a retrospective analysis 
of data extracted from the “Disease Analyzer™” database, including anonymized 
data from medical files of the patients seen by a representative sample of FrenchGP. 
Children with AD diagnosed before 1 year old were tracked for 12-months after the 
date of diagnosis. Only children monitored at least 1 year after the diagnosis were 
included in the analysis. Costs of AD treatments were calculated from a societal 
perspective. Results: 49 children with AD were treated by the emollient (group 1) 
and 59 were not (group 2). 59.2% of children of group 1 were treated by CS vs 72.9% in 
group 2; the same trend was found for the prescription of antiseptic (24.5%-vs-27.1%) 
and antibiotic (10.2%-vs-13.6%). On the contrary, healing was more prescribed in the 
emollient group (32.7%-vs-25.4%). Average annual cost of prescribed dermatological 
drugs was estimated to be 139.8 € in the emollient group and 146.4 € in the other 
group. cOnclusiOns: These preliminary results suggest that CS, which may have 
negative effects (skin fragility, infection, addiction and impact on growth), are less 
prescribed in the emollient group. Studies considering larger samples are warranted 
to confirm this trend.
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Objectives: Limited data is published on baseline characteristics of patients diag-
nosed with vitreomacular traction (VMT) or different macular hole (MH) stages. Aim 
of our study was to describe the baseline patient and ocular characteristics, and 
the management of patients diagnosed with diseases of the vitreomacular inter-
face. MethOds: This was an observational study with retrospective design. The study 
sample included patients from a large tertiary care ophthalmology center in Flanders, 
who had at least 1 outpatient visit at the study center between July 2009 and May 
2013. Patients presented with or without visual symptoms and were examined using 
optical coherence tomography (OCT) in both eyes. Patients diagnosed with other 
retinal diseases were excluded from this study. This analysis reports on the VMT 
cohort only. Results: The study sample included a total of 509 patients of which 
156 patients (191 eyes) presented with VMT. Mean (SD) age was 72.8 (9.8); 59% were 
female. Majority (73%) was referred by an ophthalmologist for symptoms of general 
vision loss (60%) and/or metamorphopsia (23%). Mean follow-up was 1.64 years. Eyes 
in which a vitrectomy was performed (n= 41) presented with worse visual acuity 
(VA) compared with eyes managed through observation (0.43 versus 0.55; p= 0.029). 
However, VA in fellow eye was significantly better in eyes managed with vitrectomy 
(0.7 versus 0.56, p= 0.039). Metamorphopsia (61% versus 37%, p= 0.005) and concomi-
tant ERM (20% versus 9%, p= 0.049) were significantly more prevalent in eyes man-
aged through vitrectomy compared with observation. cOnclusiOns: In a real-life 
population, visiting the outpatient clinic of a large tertiary care ophthalmology center, 
31% of patients presented with VMT. Patients were predominantly managed though 
observation. Worse visual acuity of fellow eye, and presence of metamorphopsia or 
ERM were significantly associated with occurrence of vitrectomy.
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Objectives: To assess the diseases associated with AD or that take over during 
the years following the diagnosis of the infant and to calculate the annual cost of 
treating these children. MethOds: The cohort includes infants with AD who have 
undergone consultation with their general practitioners between the beginning of 
2000 to the end of 2003. The data gathered through the IMS database was entered by 
general practitioners, enabling tracking of patients. The tracking period was started 
after diagnosis. Only infants who were monitored for a minimum of one-year were 
included. A control group comprising infants without AD and who were monitored 
for at least a year was created. Results: A total of 723 infants who met the criteria 
outlined were identified. In the first year following their birth, infants with AD had 
significantly more concomitant disorders, particularly respiratory disorders (85% 
vs. 76%), and asthma (8.9% vs 4.6%) or other types of dermatosis (46.9% vs. 28.2%) 
among others. During the nine-years of monitoring, the children of the AD cohort 
consumed more dermatological products than the children of the control-group did 
in terms of emollients or topical corticosteroids. As well, the AD group consumed 
more antiseptic products than the control group did in the first year (27.6% vs 14%). 
Children with AD were observed to consume more anti-asthma drugs, with a peak 
occurring at age 4. cOnclusiOns: From an epidemiological perspective, this study 
Objectives: The main aims of this systematic review were to identify all relevant 
literature on clinical efficacy for biological medications in patients with psoriasis 
and to conduct an up-to-date meta-analysis. MethOds: The following compara-
tors were considered for this analysis: adalimumab, etanercept, infliximab, and 
ustekinumab. A MEDLINE search was conducted until March 2013. The Cochrane 
Highly Sensitive Search Strategy was applied to identify randomized controlled 
publications and was combined with ‘psoriasis’ MeSH terms and drug names. 
Randomized, controlled, clinical trials with adults with moderate-to-severe pso-
riasis where the full paper can be obtained were included. Evidences were com-
bined in a mixed treatment comparisons in a Bayesian framework. Efficacy was 
measured by the 75% and 90% improvement of Psoriasis Area Severity Index (PASI) 
at three months were analysed. Results: Nineteen trials were included in this 
indirect comparison; treatment arms with off-label dosages were excluded. Each 
biologic showed significantly more favourable effect than placebo with respect to 
any level of PASI response. Significantly more patients on infliximab treatment 
met PASI75 endpoint than on etanercept, adalimumab or ustekinumab, combined 
odds ratios (95% confidence intervals) were 5.34 (2.29-12.50), 7.49 (3.31-16.92) and 
3.64 (1.62-8.20) respectively. Similarly, significantly more patients on infliximab 
treatment met PASI90 endpoint than on adalimumab or etanercept, odds ratios 
were 6.12 (1.07-34.86) and 7.78 (1.02-59.01). No significant differences in terms of 
PASI75 and PASI90 improvements were observed between adalimumab, etanercept 
or ustekinumab. cOnclusiOns: All biologics demonstrated statistically significant 
improvements compared to placebo. This review also showed that infliximab was 
significantly more efficacious than other biologics.
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Objectives: To evaluate the comparative effectiveness of bimatoprost 0.03%/
timolol (BTFC) 0.5% preservative-free (PF) fixed combination solution in single 
dose vials (BTFC PF) for the treatment of glaucoma/ocular hypertension (OHT) 
compared to alternative combination therapies accounting for fluctuations in 
intraocular pressure (IOP). MethOds: A systematic review was conducted to iden-
tify randomised controlled trials investigating efficacy of combination therapies 
for the treatment of glaucoma/OHT; where efficacy is defined as IOP change from 
baseline. Maximum and minimum changes in IOP were used as a representa-
tion of peak and trough effects of medication. Prostaglandin/prostamide analog 
and timolol monotherapy trials were also included as key connectors. A Bayesian 
mixed treatment comparison (MTC) analysis was used to synthesise the resulting 
evidence base. Supportive probability of best and rankogram summary analysis 
were used to position treatments within the network based on efficacy. Results: 
A total of 136 studies met the pre-determined MTC inclusion criteria in total; 
representing 24 unique treatment arms. BTFC PF was numerically superior to all 
treatments (monotherapies and combination therapies; preserved and PF thera-
pies) in lowering IOP efficacy in both peak and trough analyses. This superiority 
was statistically significant (p< 0.05) for 18/23 comparisons in both analyses. Lack 
of evidence is the likely reason for non-significance in remaining comparisons. The 
probability of the BTFC formulations (preserved or PF) being the best treatments 
in the network was 0.94 (94% chance) in the peak analysis and 0.90 (90% chance) 
in the trough analysis; BTFC PF specifically had a 57% chance in the peak analysis 
and 62% chance in the trough analysis. No other treatments had > 6% chance. 
Overall ranking of BTFC PF and BTFC preserved in terms of IOP-lowering efficacy 
was 1st and 2nd respectively. cOnclusiOns: BTFC PF showed the greatest clinical 
efficacy of any combination- or mono-therapy in reducing IOP from baseline in 
patients with glaucoma and/or OHT.
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Objectives: There is limited published evidence on demographic and vitreoretinal 
interface (VRI) characteristics of patients with vitreomacular traction (VMT), includ-
ing when associated with macular hole (VMT+MH). Establishing insights into the 
characteristics of untreated VMT patients may contribute to a better understanding 
of the burden of VMT disease. The objective of our analysis is to describe baseline 
patient characteristics and VRI features in patients with persistent VMT included in 
the phase 3 ocriplasmin studies. This analysis reports on VMT patients without MH 
(VMT) and VMT patients with MH (VMT+MH). MethOds: Two randomized, double-
masked, placebo-controlled trials designed to determine efficacy and safety of ocri-
plasmin for the treatment of VMT comprising of 652 patients (VMT n= 499; VMT+MH 
n= 153). Baseline characteristics included patient demographics (age, gender); eye-
disorder characteristics (time since diagnosis, visual acuity (VA) in study eye (SE); VA 
in non-study eye (NSE), presence of pseudophakia and/or ERM; VRI features (focal 
adhesion ≤ 1500 microns; min-max MH width), VFQ-25 composite score. Results: 
Baseline characteristics for VMT vs. VMT+MH patients were respectively: 72.6 ver-
sus 68.7 years; 62.7% versus 75.8% female. Time since diagnosis: 268 days versus 
62 days; VA: SE 66.8 versus 55.9, NSE 73.5 versus 77.8. Pseudophakes: 38.7% ver-
sus 20.9%, concomitant ERM: 46.3 % versus 15.8%. The majority of VMT patients 
presented with focal adhesion ≤ 1500 microns (69%) while VMT+MH patients pre-
sented with a min-max hole width of 272.7 microns. VFQ-25 composite score: 78.0 
vs. 80.3. cOnclusiOns: Baseline characteristics of the MIVI-TRUST ocriplasmin 
patient population show differentiations between patients with persistent VMT 
